Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
-
Patent number: 12042302Abstract: Improved ingestible event markers are provided. Aspects of the markers may include the presence of a matrix layer that includes a binder and source of an electron acceptor. Alternatively or in addition to the matrix layer, aspects of the markers may include a large surface area electrode having a surface area that exceeds the surface area of the circuitry of the marker. Aspects further include methods of making and using the ingestible event markers.Type: GrantFiled: May 21, 2021Date of Patent: July 23, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Patricia Johnson, Raymond Schmidt, Anuj Patel, Kevin Cheng, Kosuke Iwai, Hooman Hafezi
-
Patent number: 12036558Abstract: To provide a temperature adjustment stage that can efficiently heat a cartridge in accordance with necessity of heating each well. A temperature adjustment stage for heating a cartridge in which a plurality of wells that store a liquid are formed. The cartridge is used in an inspection system that detects an object captured by an immunoreaction, the wells include a labeled antibody well that stores a labeled antibody that labels the object, and there is provided a structure that does not heat the labeled antibody well.Type: GrantFiled: October 24, 2018Date of Patent: July 16, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Koji Miyazaki, Hideyuki Fujii, Ko Osawa, Takanori Murayama
-
Patent number: 12037345Abstract: The invention provides a compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification, useful for inhibiting the activity of SHP2.Type: GrantFiled: July 23, 2019Date of Patent: July 16, 2024Assignees: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tadashi Shimamura, Ryo Kato, Risako Miura, Takashi Mita, Takahiro Ogawa, Yufu Sagara, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Jeffrey David St. Denis, John Walter Liebeschuetz
-
Patent number: 12030873Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.Type: GrantFiled: September 1, 2021Date of Patent: July 9, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Paul Anthony Baguley, Colin Thomas Lindley, Robert Craig Melling
-
Publication number: 20240215867Abstract: A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.Type: ApplicationFiled: January 8, 2024Publication date: July 4, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Robert AZEVEDO, Neraj P. BOBRA, Aditya DUA, Ronny X. LI, William A. WEEKS
-
Publication number: 20240216389Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: ApplicationFiled: March 13, 2024Publication date: July 4, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
-
Publication number: 20240208999Abstract: Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.Type: ApplicationFiled: January 18, 2024Publication date: June 27, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kazuhiro OHDACHI, Yusuke FUJIMORI, Naoya MAKITA, Noritaka KOSEKI, Hideki HAYASHI, Yuki SAKAMOTO, Kurumi MINENO, Ryosuke TAGA
-
Patent number: 12018324Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.Type: GrantFiled: April 25, 2018Date of Patent: June 25, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori Katsuragi, Hideaki Tanaka, Ryuta Ito, Daisuke Koga
-
Patent number: 12016927Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s?1, as measured.Type: GrantFiled: December 30, 2022Date of Patent: June 25, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
-
Publication number: 20240158380Abstract: Provided are an amorphous solid dispersion containing compound (I), an amorphous form containing compound (I) and an organic acid, an amorphous solid dispersion containing the amorphous form, a pharmaceutical composition containing the amorphous form or the amorphous solid dispersion, and preparation methods for these.Type: ApplicationFiled: February 16, 2022Publication date: May 16, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Naoki Kamada, Motoyasu YOSHIMURA, Mariko KIMOTO
-
Publication number: 20240156811Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (1) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.Type: ApplicationFiled: August 25, 2023Publication date: May 16, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
-
Patent number: 11980690Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.Type: GrantFiled: June 1, 2023Date of Patent: May 14, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Syed Asfar Mateen, Praveen Kumar Mididoddi, Shailly Mehrotra, Susan Elizabeth Shoaf, Salin Gupta, Kai Suzuki, Masahiro Hasegawa
-
Publication number: 20240148699Abstract: The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.Type: ApplicationFiled: January 5, 2024Publication date: May 9, 2024Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Minoru Okada, Masaya Kato, Norifumi Sato, Tetsuyuki Uno, Hideki Kitagaki, Junpei Haruta, Hidetaka Hiyama, Tomonori Shibata
-
Publication number: 20240131169Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.Type: ApplicationFiled: September 5, 2023Publication date: April 25, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Thomas Daniel HEIGHTMAN, Honorine LEBRAUD
-
Patent number: 11963971Abstract: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.Type: GrantFiled: April 28, 2023Date of Patent: April 23, 2024Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Aram Oganesian, Nipun Davar, Jim Hwaicher Kou
-
Patent number: 11957691Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.Type: GrantFiled: September 15, 2021Date of Patent: April 16, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
-
Patent number: 11957642Abstract: An internal substance supplier includes a conveying mechanism including a conveying member configured to capture and convey an internal substance, and a supply mechanism including a scraping member disposed to cross a conveyance route of the substance by the conveying member in the conveying mechanism and configured to collide with the substance conveyed by the conveying member, a gliding member including a recessed groove configured to guide the substance colliding with the scraping member and scraped from the conveying member, to be adjacent to a position vertically above a die bore in a table in a compression-molding machine, and a push transfer member including a projection configured to come into contact with the substance, push the substance to a start edge of the recessed groove in the gliding member, and move along the recessed groove to transfer the substance to an end edge of the recessed groove.Type: GrantFiled: April 22, 2022Date of Patent: April 16, 2024Assignees: KIKUSUI SEISAKUSHO LTD., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yuji Tsujiura, Tomohiro Kakitani, Shohei Yamada, Akihiro Sawada, Shinshu Unida
-
Patent number: 11950615Abstract: An apparatus includes a food product, at least one ingestible device associated with the food product to communicate information and at least one coating material surrounding the at least one ingestible device is disclosed. The ingestible device is associated with an ingestible medication to be ingested in conjunction with the food product. The coating is configured to release the at least one ingestible device upon the occurrence of an event.Type: GrantFiled: November 10, 2021Date of Patent: April 9, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Lawrence Arne, Mark Zdeblick, Aditya Dua, George Savage, Robert Leichner, Jafar Shenasa, Patricia Johnson, Raymond Schmidt, Zahedeh Hatamkhany, Veeraperumanallu Muralidharan
-
Publication number: 20240109842Abstract: Provided is an acrylamide compound, which is useful for the promotion of platelet production from platelet progenitor cells such as megakaryocytes in vitro and represented by general formula [I]: wherein each symbol is as defined in the description.Type: ApplicationFiled: December 8, 2020Publication date: April 4, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hideki HAYASHI, Ryosuke TAGA, Yuki SAKAMOTO, Nozomi KUWANO, Kurumi MINENO, Kazuhiro OHDACHI, Yusuke FUJIMORI
-
Patent number: 11939321Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: April 7, 2021Date of Patent: March 26, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts